Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration and is marketed in the United States as NERLYNX® (neratinib) tablets. It is also approved in more than 60 countries outside the United States. In 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Puma is focused on the development of alisertib for the treatment of small cell lung cancer and breast cancer.
Puma was founded in September 2010 as a private company and incorporated in Delaware.
On October 4, 2011, Puma completed a reverse merger with Innovative Acquisitions Corp., a publicly reporting “shell” company with no specific business plan or purpose. As a result of the merger, Puma became a wholly owned subsidiary of Innovative Acquisitions. The merged company changed its name to Puma Biotechnology and adopted Puma’s business plan. The company’s common stock began trading on April 20, 2012.
Puma Biotechnology moved its common stock listing to the Nasdaq Stock Market on January 3, 2017, and trades under the symbol "PBYI." From October 19, 2012, through December 30, 2016, PBYI was listed on the New York Stock Exchange. Previously, PBYI was quoted on the OTC Bulletin Board and OTCQB Market.
As of December 31, 2025, there were 50.4 million shares of Puma Biotechnology common stock outstanding.
The CUSIP number for Puma Biotechnology common stock is 74587V107.
No.
No.
EQ Shareowner Services SM.
EQ Shareowner Services SM P.O. Box 64854 St Paul, MN 55164 Phone: (1) 800-468-9716 Website: www.shareowneronline.com
KPMG LLP
December 31.
The 2026 annual meeting of stockholders will be held at 1:00 p.m. PT on June 11, 2026, at Puma's headquarters in Los Angeles.
Puma’s headquarters are located at 10880 Wilshire Blvd., Suite 2150, Los Angeles, CA 90024.
Puma’s financial statements and other reports filed with the SEC are available on the SEC Filings page of our website.
Please contact Mariann Ohanesian, Senior Director, Investor Relations: Phone: (1) 424-248-6500, Email: ir@pumabiotechnology.com